Aventa Genomics Marks a Key Milestone in Cancer Diagnostics
Aventa™ Genomics, LLC has achieved a significant milestone by receiving a favorable pricing determination from the Centers for Medicare and Medicaid Services (CMS) for its innovative Aventa FusionPlus test. This next-generation sequencing test aims to enhance cancer diagnostics by detecting critical gene fusions, translocations, and rearrangements in solid tumors using patient samples.
What is the Aventa FusionPlus Test?
The Aventa FusionPlus test is designed to analyze genetic material obtained from formalin-fixed, paraffin-embedded (FFPE) tumor tissue. By leveraging advanced 3D genomics technology, the test enhances the detection of novel breakpoints and fusion partners, boasting a signal amplification of 100 to 1000 times compared to conventional methods. This groundbreaking approach not only reveals actionable biomarkers but also identifies those that traditional methodologies often overlook.
The Importance of Favorable Pricing
Chris Roberts, Executive Director for Aventa Genomics, expressed the significance of obtaining favorable pricing from CMS, stating, "This determination highlights the importance of innovation in cancer diagnostics and enables us to continue to expand clinician access to our novel 3D genomics-based test." By integrating the Aventa FusionPlus into cancer diagnosis and management, the company aims to improve outcomes for patients with solid tumors.
Decision Impacts on Healthcare Providers
This pricing determination reflects the growing recognition of the need for advanced diagnostic tools in oncology. In addition, the Aventa FusionPlus test was granted a Proprietary Laboratory Analysis (PLA) code, which streamlines the process for healthcare providers to incorporate this test into patient care. Starting January 1, 2025, the pricing for the Aventa FusionPlus test will be effective, facilitating its broader implementation in clinical settings.
Accessing the Aventa FusionPlus Test
Aventa Genomics ensures that healthcare professionals can easily access and order the Aventa FusionPlus test through their laboratory services. Detailed information for providers, including requisition forms, is readily available on the company's official website.
About Aventa Genomics
Aventa Genomics, LLC specializes in the application of 3D genomics to improve patient outcomes. As a subsidiary of Arima Genomics, Inc., Aventa is dedicated to utilizing innovative tools for the identification of druggable targets in cancer treatment. Their flagship Aventa FusionPlus test stands as a testament to their commitment to advancing cancer diagnostics.
About Arima Genomics Inc.
Arima Genomics is on a mission to enhance human health by unlocking comprehensive insights into genomic structures. Their advanced technologies provide researchers and clinicians with a deep understanding of the three-dimensional organization of the genome, facilitating progress in identifying biomarkers and developing new therapeutic solutions for better patient management.
Frequently Asked Questions
1. What is the significance of the CMS pricing determination?
The CMS pricing determination is a critical milestone that facilitates access to the Aventa FusionPlus test, allowing more clinicians to incorporate advanced diagnostics into their practices.
2. How does the Aventa FusionPlus test differ from traditional methods?
The Aventa FusionPlus test utilizes 3D genomics technology, which significantly enhances the detection capabilities and reveals biomarkers often missed by conventional tests.
3. When will the pricing for the Aventa FusionPlus test take effect?
The CLFS pricing for the Aventa FusionPlus test will become effective on January 1, 2025.
4. How can healthcare providers order the Aventa FusionPlus test?
Healthcare providers can order the Aventa FusionPlus test by accessing detailed requisition forms available on the Aventa Genomics website.
5. What role does Arima Genomics play in Aventa Genomics?
Arima Genomics, as the parent company of Aventa Genomics, supports the development and implementation of advanced genomic technologies aimed at improving cancer diagnosis and treatment.
